Proficio Capital Partners LLC Buys 144,099 Shares of Moderna, Inc. (NASDAQ:MRNA)

Proficio Capital Partners LLC lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 4,418.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,360 shares of the company’s stock after acquiring an additional 144,099 shares during the period. Proficio Capital Partners LLC’s holdings in Moderna were worth $6,127,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in MRNA. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new position in shares of Moderna during the fourth quarter worth about $37,000. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after acquiring an additional 388 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Down 2.2 %

Shares of NASDAQ:MRNA opened at $30.27 on Tuesday. The stock has a market cap of $11.68 billion, a PE ratio of -3.26 and a beta of 1.59. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The business has a 50 day moving average of $37.12 and a 200-day moving average of $50.28.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Wolfe Research began coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. UBS Group decreased their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. set a $45.00 target price on Moderna in a report on Friday, February 14th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.